Chemotherapy Patients on hormone therapy whose tumors have progressed are candidates for cytotoxic chemotherapy. There are no data suggesting that combination therapy results in an OS benefit over single-agent therapy. Patients with hormone receptor-negative tumors and those with visceral metastases or symptomatic disease are also candidates for cytotoxic agents. The selection of therapy in individual patients is influenced by the following: Rate of disease progression. Presence or absence of comorbid medical conditions. Physician/patient preference. Decisions regarding the duration of chemo. may consider the following: Patient preference and goals of treatment. Presence of toxicities from previous therapies. Availability of alternative treatment options.
Source: NCI 2019